The relationship between use of SGLT2is and incidence of respiratory and infectious diseases and site-specific fractures: a meta-analysis based on 32 large RCTs

Wang, Yueping; Zhou, Xian

doi:10.1007/s00228-024-03631-7

Cited by 3 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, more and more real-world studies have revealed the obvious benefits of SGLT2 inhibitors against many respiratory diseases, such as chronic obstructive pulmonary disease (COPD) (Pradhan et al, 2022), pneumonia (Wu et al, 2022), obstructive airway disease (Au et al, 2023), pulmonary edema (Jeong et al, 2023), and respiratory failure (Jeong et al, 2023). Similar with these real-world evidences, several meta-analyses (Yin et al, 2021;Li et al, 2022;Wang et al, 2022;Wang and Zhou, 2024;Xiao et al, 2024) based on RCTs have also revealed the respiratory system benefits of SGLT2 inhibitors. A meta-analysis (Yin et al, 2021) of 9 RCTs showed that use of gliflozins was significantly associated with the lower risks of multiple respiratory diseases, such as COPD, and asthma.…”

Section: Introductionsupporting

confidence: 61%

“…A meta-analysis ( Yin et al, 2021 ) of 9 RCTs showed that use of gliflozins was significantly associated with the lower risks of multiple respiratory diseases, such as COPD, and asthma. One other meta-analysis ( Xiao et al, 2024 ) of 14 RCTs and another meta-analysis ( Wang and Zhou, 2024 ) of 32 RCTs produced the substantially consistent findings. Moreover, two other studies ( Li et al, 2022 ; Wang et al, 2022 ) of meta-analysis based on RCTs revealed that use of gliflozins was significantly associated with less pneumonia and asthma, respectively.…”

Section: Introductionmentioning

confidence: 70%

See 1 more Smart Citation

Relative efficacy of five SGLT2 inhibitors: a network meta-analysis of 20 cardiovascular and respiratory outcomes

Huang,

Hu,

Zou

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 61%

Section: Introductionmentioning

confidence: 70%

Relative efficacy of five SGLT2 inhibitors: a network meta-analysis of 20 cardiovascular and respiratory outcomes

Huang,

Hu,

Zou

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 61%

“…A meta-analysis (Yin et al, 2021) of 9 RCTs showed that use of gliflozins was significantly associated with the lower risks of multiple respiratory diseases, such as COPD, and asthma. One other meta-analysis (Xiao et al, 2024) of 14 RCTs and another meta-analysis (Wang and Zhou, 2024) of 32 RCTs produced the substantially consistent findings. Moreover, two other studies (Li et al, 2022;Wang et al, 2022) of meta-analysis based on RCTs revealed that use of gliflozins was significantly associated with less pneumonia and asthma, respectively.…”

Section: Introductionmentioning

confidence: 69%

Image1.PDF

View full text Add to dashboard Cite

In nondiabetic C57BL/6J mice, canagliflozin affects the skeleton in a sex- and age-dependent manner

Chlebek,

McAndrews,

Costa

et al. 2024

JBMR Plus

View full text Add to dashboard Cite

Canagliflozin (CANA) is a sodium glucose cotransporter-2 inhibitor that reduces blood glucose levels. Sodium glucose cotransporter-2 (SGLT2) is primarily expressed in the kidney, but not in any bone cells, therefore effects on the skeleton are likely to be non-cell autonomous. Originally developed to treat Type II Diabetes, CANA use has expanded to treat cardiovascular and renovascular disease. Clinical trials examining CANA in diabetic patients have produced contradictory reports on fracture risk, but there are limited data of CANA in nondiabetic conditions. In nondiabetic preclinical models, short-term treatment with CANA negatively affected trabecular bone whereas long-term treatment reduced cortical bone mineralization in male but not female mice. To investigate the skeletal effects of an intermediate period of CANA treatment, we treated male and female C57BL/6 J mice with CANA (180 ppm) for 6 months. Age at treatment initiation was also evaluated, with cohorts starting CANA prior to skeletal maturity (3-months-old) or in adulthood (6-months-old). Longitudinal assessments of bone mineral density revealed early benefits of CANA treatment in female mice. At euthanasia, both trabecular and cortical bone morphology were improved by CANA treatment in males and females. Bone formation was reduced at the endosteal surface. Canagliflozin decreased osteoblast number in male mice and bone marrow adiposity in females. Overall, more skeletal benefits were recorded in CANA-treated females than males. Urinary calcium output increased with CANA treatment, but parathyroid hormone was not changed. Despite reduced fasting blood glucose, body composition and whole-body metabolism were minimally changed by CANA treatment. For all outcome measures, limited differences were recorded based on age at treatment initiation. This study demonstrated that in nondiabetic C57BL/6 J mice, an intermediate period of CANA treatment improved bone morphology, but reduced osteoblast and bone marrow adipocyte number as well as serum P1NP in a sex-specific manner.

show abstract

The relationship between use of SGLT2is and incidence of respiratory and infectious diseases and site-specific fractures: a meta-analysis based on 32 large RCTs

Cited by 3 publications

References 56 publications

Relative efficacy of five SGLT2 inhibitors: a network meta-analysis of 20 cardiovascular and respiratory outcomes

Relative efficacy of five SGLT2 inhibitors: a network meta-analysis of 20 cardiovascular and respiratory outcomes

Image1.PDF

In nondiabetic C57BL/6J mice, canagliflozin affects the skeleton in a sex- and age-dependent manner

Contact Info

Product

Resources

About